Royalty Pharma (RPRX) total liabilities
Royalty Pharma (RPRX) had total liabilities of $9.91B at the end of fiscal 2025 (December 31, 2025). That is 25.7% higher than the $7.88B of fiscal 2024. Figures as of 18 Nov 2026, 20:14 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $9.91B
- Change on fiscal 2024
- +25.7%
- Growth, 5 years
- +10.1% a year
- Highest on record
- $9.91Bfiscal 2025
- Lowest on record
- $6.12Bfiscal 2020
- Fiscal years on record
- 72019–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Royalty Pharma total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities grew at a compound 10.1% a year. Across the 7 fiscal years on record (2019–2025), the highest was $9.91B in fiscal 2025 and the lowest $6.12B in fiscal 2020.
Total liabilities by fiscal year
Royalty Pharma total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $9.91B | 25.7% up | |
| 2024 | $7.88B | 25.1% up | |
| 2023 | $6.30B | 13.6% down | |
| 2022 | $7.29B | 0.3% up | |
| 2021 | $7.27B | 18.7% up | |
| 2020 | $6.12B | 2.9% down | |
| 2019 | $6.31B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Royalty Pharma, figure by figure
- Royalty Pharma market cap
- Royalty Pharma revenue
- Royalty Pharma earnings
- Royalty Pharma earnings per share (EPS)
- Royalty Pharma P/E ratio
- Royalty Pharma P/S ratio
- Royalty Pharma P/B ratio
- Royalty Pharma free cash flow
- Royalty Pharma operating margin
- Royalty Pharma dividend
- Royalty Pharma shares outstanding
- Royalty Pharma total debt
- Royalty Pharma cash on hand
- Royalty Pharma total assets
- Royalty Pharma net assets (shareholders' equity)
- Royalty Pharma return on equity (ROE)
- Royalty Pharma return on invested capital (ROIC)
Royalty Pharma (RPRX) overview: price, valuation and scorecardAll health care companies by market value
Royalty Pharma total liabilities: questions and answers
How large are Royalty Pharma's total liabilities?
Royalty Pharma (RPRX) had total liabilities of $9.91B at the end of fiscal 2025 (December 31, 2025). That is 25.7% higher than the $7.88B of fiscal 2024.
What is the growth rate of Royalty Pharma's total liabilities?
Over the five fiscal years to 2025 total liabilities grew at a compound 10.1% a year.
What are the highest and lowest total liabilities figures on record for Royalty Pharma?
Across the 7 fiscal years on record (2019–2025), the highest was $9.91B in fiscal 2025 and the lowest $6.12B in fiscal 2020.
How is Royalty Pharma's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Royalty Pharma it is on record here for 7 fiscal years, 2019 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Royalty Pharma (RPRX) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/RPRX/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.